Login to Your Account



Actelion Moves Oral Prostacyclin Analogue into Phase III Studies

By Cormac Sheridan


Wednesday, July 22, 2009
With positive data from a Phase IIa trial in hand, Actelion AG plans to move directly into a Phase III morbidity/mortality trial of its first-in-class oral prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (PAH) before year-end. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription